FROVATRIPTAN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C14H17N3O
Molecular Weight	243.3048
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN[C@]1([H])CCc2c(C1)c3cc(ccc3[nH]2)C(=N)O

InChI

InChIKey=XPSQPHWEGNHMSK-SECBINFHSA-N

InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C14H17N3O
Molecular Weight	243.3048
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021006s006s009s010lbl.pdf

Frovatriptan succinate (trade name Frova) is a selective 5-hydroxytryptamine1 (5-HT1B/1D) receptor subtype agonist, and is used for the treatment of migraine attacks with or without aura in adults. Frovatriptan has no significant effects on GABAA mediated channel activity and has no significant affinity for benzodiazepine binding sites. Frovatriptan is believed to act on extracerebral, intracranial arteries and to inhibit excessive dilation of these vessels in migraine. Serious but rare cardiac events have been reported in patients with risk factors predictive of coronary artery disease (CAD). These include coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Serotonin 1a (5-HT1a) receptor 162 Target ID: CHEMBL214 Sources: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5618948.PN.&OS=PN/5618948&RS=PN/5618948	Agonist 2470	62.0 nM [Ki]
Serotonin 1b (5-HT1b) receptor 37 Target ID: CHEMBL1898 Sources: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5618948.PN.&OS=PN/5618948&RS=PN/5618948	Agonist 2470	10.3 nM [Ki]
Serotonin 1d (5-HT1d) receptor 46 Target ID: CHEMBL1983 Sources: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5618948.PN.&OS=PN/5618948&RS=PN/5618948	Agonist 2470	4.4 nM [Ki]
Serotonin 1d (5-HT1d) receptor 46 Target ID: CHEMBL1983 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021006s006s009s010lbl.pdf	Agonist 2470
Serotonin 1b (5-HT1b) receptor 37 Target ID: CHEMBL1898 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021006s006s009s010lbl.pdf	Agonist 2470

Conditions

Condition	Modality	Targets	Highest Phase	Product
Migraine with aura 11 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021006s006s009s010lbl.pdf	Primary		Approved 8043	FROVA Approved Use FROVA is indicated for the acute treatment of migraine attacks with or without aura in adults. FROVA is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). The safety and effectiveness of FROVA have not been established for cluster headache, which is present in an older, predominately male, population. Launch Date 1.0051776E12
Migraine without aura 7 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021006s006s009s010lbl.pdf	Primary		Approved 8043	FROVA Approved Use FROVA is indicated for the acute treatment of migraine attacks with or without aura in adults. FROVA is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). The safety and effectiveness of FROVA have not been established for cluster headache, which is present in an older, predominately male, population. Launch Date 1.0051776E12

C_max

Value	Dose	Co-administered	Analyte	Population
2.44 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25092964	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:		FROVATRIPTAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
50.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25092964	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:		FROVATRIPTAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
29.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25092964	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:		FROVATRIPTAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
85% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf			FROVATRIPTAN serum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.8 mg single, intravenous Highest studied dose Dose: 0.8 mg Route: intravenous Route: single Dose: 0.8 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12028321 Page: S56	healthy, 21 - 37 n = 12 Health Status: healthy Age Group: 21 - 37 Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/12028321 Page: S56	Sources: https://pubmed.ncbi.nlm.nih.gov/12028321 Page: S56
40 mg single, oral Highest studied dose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12028321 Page: S56	healthy, 21 - 37 n = 12 Health Status: healthy Age Group: 21 - 37 Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/12028321 Page: S56	Sources: https://pubmed.ncbi.nlm.nih.gov/12028321 Page: S56
40 mg single, oral Highest studied dose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12028323 Page: S76	unhealthy, 40.4 n = 207 Health Status: unhealthy Condition: Migraine Age Group: 40.4 Sex: M+F Population Size: 207 Sources: https://pubmed.ncbi.nlm.nih.gov/12028323 Page: S76	Sources: https://pubmed.ncbi.nlm.nih.gov/12028323 Page: S76
7.5 mg 3 times / day multiple, oral Recommended Dose: 7.5 mg, 3 times / day Route: oral Route: multiple Dose: 7.5 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf Page: p.1	Disc. AE: Arrhythmia, Cerebral hemorrhage... Other AEs: Myocardial ischemia, Myocardial infarction... AEs leading to discontinuation/dose reduction: Arrhythmia Cerebral hemorrhage Subarachnoid hemorrhage Stroke Gastrointestinal ischemia Peripheral vasoconstriction Serotonin syndrome Other AEs: Myocardial ischemia Myocardial infarction Prinzmetal angina Chest pain Throat pain Neck pain Jaw pain Chest tightness Throat tightness Pressure Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf Page: p.1
7.5 mg 3 times / day multiple, oral Recommended Dose: 7.5 mg, 3 times / day Route: oral Route: multiple Dose: 7.5 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf Page: p.3	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf Page: p.3	Disc. AE: Splenic infarction, Raynaud's syndrome... AEs leading to discontinuation/dose reduction: Splenic infarction Raynaud's syndrome Blood pressure high (grade 3) Hypertensive crisis Anaphylactic reaction (grade 4-5) Anaphylactoid reaction (grade 4-5) Angioedema (grade 4-5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf Page: p.3

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1467 inducer 707 substrate 1601	substrate 936	inhibitor 1702 substrate 1118

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1383 CYP2C8/9 43 CYP2C19 1325 CYP2E1 790	CYP1A2 972	CYP1A2 637 CYP4A 11

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1532	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-006_Frova_biopharmr.pdf Page: 29, 35	no
CYP1A2 1532	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-006_Frova_biopharmr.pdf Page: 35.0	no
CYP2C19 1392	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-006_Frova_biopharmr.pdf Page: 35.0	no
CYP2C8/9 43	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-006_Frova_biopharmr.pdf Page: 35.0	no
CYP2D6 1738	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-006_Frova_biopharmr.pdf Page: 35.0	no
CYP2E1 871	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-006_Frova_biopharmr.pdf Page: 35.0	no
CYP3A4 1772	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-006_Frova_biopharmr.pdf Page: 29, 35	no
CYP3A4 1772	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-006_Frova_biopharmr.pdf Page: 35.0	no
CYP4A 29	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-006_Frova_biopharmr.pdf Page: 29, 35	no

Drug as victim

Target	Modality	Activity
CYP2C9 936	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-006_Frova_biopharmr.pdf Page: 35.0	no
CYP2D6 1118	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-006_Frova_biopharmr.pdf Page: 35.0	no
CYP3A4 1601	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-006_Frova_biopharmr.pdf Page: 35.0	no
CYP1A2 972	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-006_Frova_biopharmr.pdf Page: 29.0	yes

Sourcing

Vendor/Aggregator	ID	URL
ABI Chem	AC1L2U95
AN PharmaTech	AN-5267
Alsachim	4232	http://www.alsachim.com/product-C5550-glo.bal-view.html
Angene	AGN-PC-0Q7KOZ
BLD Pharm	BD131596	http://www.bldpharm.com/products/158747-02-5.html
BOC Sciences	147009-08-3
BOC Sciences	158930-09-7
BOC Sciences	158930-17-7
Chem Scene	CS-0021309
ChemMol	44000939	http://www.chemmol.com/chemmol/44000939.html
ChemMol	49400089	http://www.chemmol.com/chemmol/49400089.html
ChemShuttle	159065
Chemieliva Pharmaceutical Co., Ltd	PBCM1202367
Compound Cloud	152943
Compound Cloud	77992
DC Chemicals	DC22890	http://www.dcchemicals.com/product_show-DC22890.html
Hangzhou APIChem Technology	AC-4258
MolPort	MolPort-046-196-805
Molnova	M12269
MuseChem	M105240	https://www.musechem.com/product/M105240.html
Norris Pharm	NSZB-A219176
NovoSeek	77992
Parchem	29025	http://www.parchem.com/chemical-supplier-distributor/Frovatriptan-019025.aspx
Selleck Chemicals	S5848
Sigma Aldrich	1286413
Sigma Aldrich	1286413\|USP
Sigma Aldrich	SML1291
Sigma Aldrich	SML1291\|SIGMA
Smolecule	S528497	http://www.smolecule.com/products/s528497
THE BioTek	bt-268779	https://www.thebiotek.com/product/inhibitors/bt-268779
THE BioTek	bt-406286	https://www.thebiotek.com/product/others/bt-406286
Toronto Research Chemicals	M198100
Wonderchem	WD05AWA
Wonderchem	WD05AWB
ZINC	ZINC000000018635	http://zinc15.docking.org/substances/ZINC000000018635
eMolecules	225791104
eMolecules	300452900
eMolecules	45916583
eMolecules	48667526
eMolecules	76760210
eNovation Chemicals	D380881

PubMed

Title	Date	PubMed
Evaluation of Frova, single-use intubation introducer, in a manikin. Comparison with Eschmann multiple-use introducer and Portex single-use introducer.	2004 Aug	15270974
Frovatriptan for the treatment of cluster headaches.	2004 Dec	15566418
Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine.	2004 Jul	15311727
Involvement of 5-HT1B receptors in triptan-induced contractile responses in guinea-pig isolated iliac artery.	2004 Jul	15185063
A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.	2004 Jul 27	15277618
Menstrual migraine: timing is everything.	2004 Jul 27	15277607
Gateways to clinical trials.	2004 Jun	15319815
Gateways to clinical trials.	2004 May	15319808
Tracheostomy must be individualized!	2004 Oct	15469591
Pharmacokinetics of frovatriptan in adolescent migraineurs.	2004 Oct	15342617
[Meta-analysis of triptan treatment in migraine].	2004 Sep	15552863
Gateways to clinical trials.	2004 Sep	15538546
Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe.	2004 Sep	15383196
Regulatory and functional interactions of plant growth regulators and plant glutathione S-transferases (GSTs).	2005	16492471
The use of triptans in the management of menstrual migraine.	2005	16268666
Efficacy and tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials.	2005 Dec	16336284
Evidence for 5-HT2B and 5-HT7 receptor-mediated relaxation in pulmonary arteries of weaned pigs.	2005 Jan	15726452
Gateways to clinical trials.	2005 Mar	15834466
A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.	2005 Mar 8	15753451
Advanced strategies of short-term prophylaxis in menstrual migraine: state of the art and prospects.	2005 May	15926009
[Tracheotomy and tracheostomy techniques].	2005 May	15827706
The use of multiattribute decision models in evaluating triptan treatment options in migraine.	2005 Sep	15761676
Frovatriptan-induced hypomania.	2005 Summer	16179674
[Clinical use of triptans in the management of migraine].	2006	16841523
Tracheal intubation using a classic laryngeal mask airway, Frova introducer, and pediatric bronchoscope.	2006 Dec	17122292
A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.	2006 Dec 20	17183637
Shearing of a Frova Intubating Introducer by a Bronchocath double lumen tube.	2006 Feb	16430585
Clinical review: percutaneous dilatational tracheostomy.	2006 Feb	16356203
A validated chiral CE method for Frovatriptan, using cyclodextrin as chiral selector.	2006 Jun 16	16672183
Gateways to clinical trials.	2006 Nov	17200730
Tailoring management strategies for the patient with menstrual migraine: focus on prevention and treatment.	2006 Oct	17044843
Frovatriptan: a review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine.	2006 Sep	18360605
Editorial foreword.	2006 Sep	18360597
Airway management during microlaryngoscopic surgery with a Frova airway intubation catheter.	2006 Sep	16980166
Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.	2007	17190530
Frovatriptan review.	2007 Dec	18001261
Chiral separation of Frovatriptan isomers by HPLC using amylose based chiral stationary phase.	2007 Feb 1	16962393
Latest pain relief a combination of new and old.	2007 Jan	17198336
New pain management options: drugs.	2007 Jan	17198138
In silico prediction of pregnane X receptor activators by machine learning approaches.	2007 Jan	17003167
Frovatriptan for the prevention of postdural puncture headache.	2007 Jul	17598763
Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans.	2007 Jul	17537184
Efficacy of frovatriptan.	2007 Jun	17578554
Frova intubating catheter position can be determined with aspirating oesophageal detection device.	2007 Jun	17564685
Menstrually related migraine: breaking the cycle in your clinical practice.	2007 Oct	17977161
Frovatriptan vs. transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine.	2007 Oct	17955167
Efficacy of frovatriptan.	2007 Sep	17883538
Acute treatment and prevention of menstrually related migraine headache: evidence-based review.	2008 Apr 22	18427072
Triptans in pregnancy.	2008 Feb	18223456
Evaluation of clinical effectiveness of the Frova single-use tracheal tube introducer.	2008 Feb	18211451

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose is a single tablet of FROVA (frovatriptan 2.5 mg) taken orally with fluids. If the headache recurs after initial relief, a second tablet may be taken, providing there is an interval of at least 2 hours between doses. The total daily dose of frovatriptan should not exceed 3 tablets (3 x 2.5 mg per day). The safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Jun 26 00:00:38 UTC 2021` Edited by `admin` on `Sat Jun 26 00:00:38 UTC 2021`
Record UNII	H82Q2D5WA7
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FROVATRIPTAN

Official Name

English

FROVATRIPTAN [HSDB]

Common Name

English

ALLERGO FILMTABLETTEN

Brand Name

English

FROVATRIPTAN [VANDF]

Common Name

English

FROVATRIPTAN [MI]

Common Name

English

FROVATRIPTAN [WHO-DD]

Common Name

English

FROVATRIPTAN [MART.]

Common Name

English

FROVATRIPTAN [INN]

Common Name

English

(R)-5,6,7,8-TETRAHYDRO-6-(METHYLAMINO)CARBAZOLE-3-CARBOXAMIDE

Systematic Name

English

Classification Tree Code System Code

NDF-RT

N0000175763